This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Free Reports

$40 Billion Takeover Has Big Pharma Giddy

Thursday's parade of deals seem to answer a question that's been bugging health care investors for most of 2016: why haven't retreating biotech valuations sparked an uptick in M&A activity?

Sarepta Can Win Speedy FDA Drug Approval

Senior FDA officials, most notably Dr. Janet Woodcock, the agency's top drug evaluator, spent a lot of time at Monday's panel making supportive statements about eteplirsen.

Sanofi Presses Medivation to Hold Talks After $9.3B Offer

The French pharmaceuticals company takes its campaign to snare the oncology specialist public.

Vertex Forecasts Billion-Dollar Sales for Cystic Fibrosis Drug in '16

Vertex Pharmaceuticals tried to soothe fears about the commercial ramp of its cystic fibrosis franchise by providing Orkambi sales guidance for the first time since the drug launched last summer.

MannKind and Its CEO Fail Simple Financial Literacy Test

MannKind is drowning in debt and fixed purchasing contracts but the company generates no revenue.

Sarepta Therapeutics FDA Panel Live Blog

An advisory committee convened by the U.S. Food and Drug Administration is reviewing Sarepta's experimental Duchenne muscular dystrophy drug.

An Investors' Guide to Sarepta's Eteplirsen FDA Advisory Panel Meeting

The FDA advisory panel review of Sarepta's DMD drug eteplirsen will be surprising, controversial, volatile, dramatic, newsworthy and memorable.

Biotech Stock Mailbag: Is There a Future for Sarepta Therapeutics?

TheStreet's Adam Feuerstein answers reader questions about biotech stocks.

FDA Still Negative on Sarepta's DMD Drug; Stock Price Sinks

The news was still negative for eteplirsen, the Duchenne muscular dystrophy drug from Sarepta Therapeutics.

Ignoring Criticism, Drug Companies Still Raising Prices, Making More Money

Efforts by insurers to negotiate higher discounts or rebates on specialty pharmaceutical products isn't keeping pace with the price increases pushed through by drug and biotech companies, an analyst says.

Page 1 of 357
< Previous
Top Rated Stocks Top Rated Funds Top Rated ETFs